Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. HOYA Corporation
  6. News
  7. Summary
    7741   JP3837800006


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

HOYA : PENTAX Medical and Vedkang Establish Endoscopic Therapeutics Joint Venture

05/31/2021 | 08:06pm EDT

PENTAX Medical and Vedkang Establish Endoscopic Therapeutics Joint Venture

May 31, 2021, Tokyo, Japan and Changzhou, China - PENTAX Medical (a division of HOYA Group) and Jiangsu Vedkang Medical Science and Technology Co., Ltd (Vedkang) today announced the establishment of a joint venture- PENTAX Medical Therapeutics (Jiangsu) Co., Ltd.(*) to develop single-use therapeutics products in the field of flexible medical endoscopy. The new company will offer innovative single-use devices to global customers through the PENTAX Medical sales network strengthened by Vedkang's exceptionally reliable and quality-focused production and R & D infrastructure.

Medical flexible endoscopes and therapeutic devices are used in minimally invasive procedures to benefit patients, physicians, and health care systems with significant reductions in procedure cost/complexity resulting in dramatic improvements in patient recovery time.

"We are excited to establish this collaboration with Vedkang to further advance our mission to improve the standard of patient care and quality of healthcare around the world. Our collaboration will support the fast-growing Endotherapy segment as new and innovative procedures achieve traction and penetration worldwide. Instilling clinical confidence by delivering high performance, reliability and value to our customers is at the core of everything we do," said Gerald W. Bottero, Global President of PENTAX Medical. "Now PENTAX Medical together with Vedkang looks forward to offering integrated endoscopy solutions to our valued global customers."

The new company, PENTAX Medical Therapeutics (Jiangsu) Co., Ltd. (*) will be headquartered in China and plans to develop and commercialize products for key markets in Europe, Asia and Americas.

"PENTAX Medical has always been a valuable business partner to Vedkang, and we are delighted to continue our close relationship in this joint venture by pursuing further possibilities with doctors and patients across the world.", said Mr. Zhuang XiaoJing, The Chairman and CEO of Vedkang.

  1. The joint-venture company's name is subjective to final government approval

About PENTAX Medical

PENTAX Medical is a division of HOYA Group. The company's mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. PENTAX Medical strives to align with the healthcare community's Triple Aim goals through transparent partnerships with its customers and by providing the highest quality solutions to help them reach their goals, including enabling customers to improve patient outcomes by offering evidence-based solutions across the continuum of care; ensuring value by supporting the customers to improve their efficiency and minimize their healthcare costs; and enriching patient and provider's

experience by empowering every member of the care team to achieve optimal outcomes through products, education, and support.

Focused on the outcome instead of technological features, PENTAX Medical listens to the healthcare community and their patients, understands their daily obstacles and helps improve endoscopy with smart innovations.

For more information: www.pentaxmedical.com

About HOYA

Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med- tech company and a leading supplier of innovative high-tech and medical products. HOYA's divisions and business units research and develop products utilized in the healthcare and information technology fields. In the healthcare field, we provide medical device products such as eyeglasses, medical endoscopes, contact and intraocular lenses, orthopedic implants, surgical/therapeutic devices and medical device reprocessing and disinfection solutions. In the information technology field, we provide products such as optical lenses, photomasks and blanks used in the manufacturing process for semiconductor and LCD/OLED devices, text to speech, human resources and other software solutions and critical components for the mass memory and cloud storage industries. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 37,000 people. For more information, please visit http://www.hoya.com

About Jiangsu Vedkang Medical Science and Technology Co., Ltd.

Located in Changzhou city, Jiangsu province, is specializes in R&D, manufacture and sales of endoscopic diagnostic & therapy medical devices. With 5000 m² standard factory and Class 100,000 cleaning room, advanced production and testing equipment ensures the price, quality and services we provide to our customers. By establishing strategic partnership with University hospitals and KOLs, our products aiming to solve

doctors' unmet needs and we are responsible to make their inspirations into products and benefit patients. To constant pursuing our values, Vedkang continues investment into advanced R&D technology, to producing better functionality, superior performance endoscopic therapy devices.

Today, Vedkang offers a complete endoscopy solution, from gastrointestinal, Respiratory,Urology to endoscopic accessories. 8Mil Pcs Vedkang product has been introduced into 2000+Hospitals in more than 50 countries.


Kaori Kawashima

GM, Corporate Communications & Product Branding

PENTAX Medical

HOYA Group

Email: kaori.kawashima@pentaxmedical.com


Hoya Corporation published this content on 01 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 June 2021 00:05:07 UTC.

ę Publicnow 2021
09/17Japanese shares post 4th weekly gain on catch-up trade, chipmakers boost
09/16Japanese shares edge up as FOMO keeps rally alive
07/31HOYA : Presentation for the three months ended Jun.30,2021 (with Transcript)
07/30Hoya to Launch Share Compensation Program
07/29HOYA : Quarterly Report for the three months ended Jun.30,2021
07/29HOYA : Notification of Issuance of Share Subscription Rights (Stock Options) to Directors ..
07/29HOYA : Presentation for the three months ended Jun.30,2021
07/29HOYA Corporation Provides Earnings Guidance for the Second Quarter and Six Months Endin..
07/29HOYA Corporation Reports Consolidated Earnings Results for the First Quarter Ended June..
07/15HOYA : IFRS Report
More news
Sales 2022 636 B 5 757 M 5 757 M
Net income 2022 160 B 1 449 M 1 449 M
Net cash 2022 378 B 3 420 M 3 420 M
P/E ratio 2022 41,9x
Yield 2022 0,52%
Capitalization 6 740 B 61 174 M 61 047 M
EV / Sales 2022 10,0x
EV / Sales 2023 9,19x
Nbr of Employees 37 245
Free-Float 98,1%
Duration : Period :
HOYA Corporation Technical Analysis Chart | 7741 | JP3837800006 | MarketScreener
Technical analysis trends HOYA CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 14
Last Close Price 18 270,00 JPY
Average target price 18 242,86 JPY
Spread / Average Target -0,15%
EPS Revisions
Managers and Directors
Hiroshi Suzuki President, Chief Executive Officer & Director
Ryo Hirooka CFO & Representative Executive Officer
Eiichiro Ikeda Chief Technology Officer & Executive Officer
Yukako Uchinaga Independent Outside Director
Mitsudo Urano Lead Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC11.52%175 817